Comparison Of Clinical Response Between Combine Chemotherapy 5 Fluorourasil - Platinum Based And Ifosfamid - Taxane - Platinum Based In Recurrent Nasopharyngeal Carcinoma
DOI:
https://doi.org/10.36408/mhjcm.v10i3.926Keywords:
Recurrent nasopharyngeal carcinoma, 5-flourouracil, ifosfamide, response to therapyAbstract
BACKGROUND : Recurrence of Nasopharyngeal Carcinoma (NPC) is the emergence of a tumor remission after administration of chemoradiation based on symptoms and several examinations. The combination of chemotherapy in recurrent NPC still gives good results. The combine of regimens used is still varied and not much study has been done to assess the clinical response.
OBJECTIVE : To compare the clinical response between administration of combination 5 Fluorouracil-Platinum based (5-FU) and Ifosfamide-taxan-platinum based (IFO) in recurrent NPC.
METHOD :. This observational study used electronic medical record (ERM) data at the ENT oncology clinic at Dr. Kariadi General Hospital for the period January 2020-January 2022. The number of samples that suited to the inclusion and exclusion criteria was 44 subjects divided into two groups of 22 subjects respectively. The chi-square test was used to assess differences in alteration of clinical symptoms, tumor mass size, neck lymph node enlargement, tumours stage reduction, and the effect of confounding factors on response to therapy in both groups.
RESULTS : The highest number of patients with recurrent NPC were aged ≥45 Years old and male (75%). WHO type 3 is the most common (95.5%) and ECOG status 1 (95.5%). There was no significant difference administration of the combination of 5-FU with IFO in alteration of clinical symptoms (p=0.500), shrink tumor size (p=0.347), reduction of neck lymph node size (p=0.164), and reduction tumor staging (p=0.347). There was no relationship from confounding factors to clinical response between the administration of the two groups.
CONCLUSION : Administration of 5 Fluorouracil-platinum based combination chemotherapy did not provide a better clinical response in terms of clinical symptoms, changes in primary tumor size, neck lymph node size, and decreased tumor stage compared to the Ifosfamide-taxane-platinum based combination based on recurrent NPC.
Downloads
References
1. Nasopharyngeal Carcinoma. Int J Nasopharyngeal Carcinoma. 2020; 02(04): 2019–21.
2. Diva P, Suta D, Andi K, Saputra D, Wulan S, Sutanegara D. Profil Penderita Kanker Nasofaring Di Rumah Sakit Umum Pusat Sanglah Denpasar Periode Januari – Desember Tahun 2014. E-Jurnal Med. 2019;8(2):1–14
3. Mott FE, Ferrarotto R, Nguyen T, Phan J. Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy. Oral Oncol. 2018;81(April):75–80.
4. Gondhowiardjo SA, Meidania L, Senoaji F, Sekarutami SM. Nasopharyngeal Carcinoma Profile in dr. Cipto Mangunkusumo Hospital Year 2013. Radioter Onkol Indones. 2020;10(1):8–11.
5. Wei WI, Chua DT. Neoplasms of the Nasophaynx. in: Wackym A, Snow Jr JB. Ballenger’s Otorhinolaryngology Head and Neck Surgery. Connecticut: People’s Medical Publishing House-USA; 2016. 4395–417.
6. Komite Penanggulangan Kanker Nasional Kemenkes RI. Panduan Penatalaksanaan Kanker Nasofaring. Kementeri Kesehat Republik Indones Kom Penanggulangan Kanker Nasional. 2015;1–56.
7. Chua DTT, Kwong DLW, Sham JST, Au GKH, Choy D. A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer. 2000;36(6):736–41.
8. Tsao SW, Tsang CM, Lo KW. Epstein-barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc B Biol Sci. 2017;372(1732).
9. Dede DS, Aksoy S, Cengiz M, Gullu I, Altundag K. Ifosfamide and doxorubicin combination chemotherapy for recurrent nasopharyngeal carcinoma patients. Asian Pacific J Cancer Prev. 2012;13(5):2225–8.
10. Siti-Azrin AH, Norsa’adah B, Naing NN. Prognostic factors of nasopharyngeal carcinoma patients in a tertiary referral hospital: a retrospective cohort study. BMC Res Notes. 2017;10(1):705.
11. Huang YC, Chang PMH, Chen MH, Chu PY, Tzeng CH, Chang SY, et al. A Study using ifosfamide and etoposide in patients with cisplatin-refractory recurrent or metastatic head and neck squamous cell carcinoma. Jpn J Clin Oncol. 2011;41(5):630–6.
12. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in indonesia: Epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012;31(4):185–96.
13. Airoldi M, Cortesina G, Giordano C, Pedani F, Bumma C. Ifosfamide in the treatment of head and neck cancer. Oncology. 2003;65:37–43.
14. Trimonika U, Yusmawan W, Marliyawati D. Perbandingan Respon Klinis Penderita Karsinoma Nasofaring Yang Mendapat Kemoterapi Cisplatin Neoadjuvant Dengan Concurrent. Diponegoro Med J (Jurnal Kedokt Diponegoro). 2018;7(2):574–85.
15. Xiao G, Y C, X Q, Wang W, Wang Y. Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer. 2013;13:226–34.
16. Susetiyo KA, Kusumastuti EH, Yusuf M, Falerina R. Clinicopathological profile of nasopharyngeal carcinoma in 2016-2019 at Dr . Soetomo General Hospital. 2022;52(1):7–12.
17. Li J, Lu T, Huang Y, Han F. Clinical Characteristics of Recurrent Nasopharyngeal Carcinoma in High-Incidence Area. 2012;2012.
18. Hashim D, Boffetta P. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Head and Neck Cancers. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Head and Neck Cancers. 2021.
19. Fadhlia, Ferawati, Irnawati. Management of Nasopharyngeal Cancer in Dr. Zainoel Abidin General Hospital Banda Aceh. Int J Nasopharyngeal Carcinoma. 2019;1(02):50–4.
20. Naomi SM, Dewi YA, Agustina H. Association between Histopathological Grading and Clinical Staging in Nasopharyngeal Carcinoma Hubungan Derajat Histopatologi dengan Stadium Klinis pada Karsinoma Nasofaring. Departemen Telinga Hidung Tenggorokan-Kepala Leher. 2018;2(2):730–7.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2023 Rio Sanjaya, Willy Yusmawan, Dwi Antono, Dwi Marliyawati, Kanti Yunika
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
